Salud financiera de hoja de balance de Embla Medical hf

Salud financiera controles de criterios 5/6

Embla Medical hf tiene un patrimonio de accionistas total de $801.7M y una deuda total de $375.9M, lo que sitúa su ratio deuda-patrimonio en 46.9%. Sus activos y pasivos totales son $1.6B y $787.0M respectivamente. El BAIT de Embla Medical hf es de $120.4M, por lo que su ratio de cobertura de intereses es de 5.9. Tiene efectivo e inversiones a corto plazo que ascienden a $91.8M.

Información clave

46.89%

Ratio deuda-patrimonio

US$375.94m

Deuda

Ratio de cobertura de intereses	5.9x
Efectivo	US$91.77m
Patrimonio	US$801.68m
Total pasivo	US$786.98m
Activos totales	US$1.59b

Actualizaciones recientes sobre salud financiera

Recent updates

Embla Medical hf.'s (CPH:EMBLA) Share Price Matching Investor Opinion

Apr 11

Here's Why Embla Medical hf (CPH:EMBLA) Can Manage Its Debt Responsibly

Mar 27

Embla Medical hf.'s (CPH:EMBLA) CEO Will Probably Find It Hard To See A Huge Raise This Year

Mar 06

Investors Met With Slowing Returns on Capital At Embla Medical hf (CPH:EMBLA)

Feb 23

Acquisition Of Fior & Gentz And New Product Launches Will Expand Neuro Orthotics Portfolio Into New Markets

Feb 09 Expansion into new markets with Fior & Gentz acquisition could boost revenue and market share through neuro orthotics.

Embla Medical hf. Just Missed EPS By 5.8%: Here's What Analysts Think Will Happen Next

Feb 09

A Look At The Intrinsic Value Of Embla Medical hf. (CPH:EMBLA)

Jan 25

We Ran A Stock Scan For Earnings Growth And Embla Medical hf (CPH:EMBLA) Passed With Ease

Jan 03

Shareholders Should Be Pleased With Embla Medical hf.'s (CPH:EMBLA) Price

Dec 16

Embla Medical hf (CPH:EMBLA) Seems To Use Debt Quite Sensibly

Nov 30

Results: Embla Medical hf. Beat Earnings Expectations And Analysts Now Have New Forecasts

Oct 25

Estimating The Intrinsic Value Of Embla Medical hf. (CPH:EMBLA)

Oct 17

Do Embla Medical hf's (CPH:EMBLA) Earnings Warrant Your Attention?

Oct 02

Embla Medical hf.'s (CPH:EMBLA) Share Price Matching Investor Opinion

Aug 22

Earnings Beat: Embla Medical hf. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models

Jul 26

Calculating The Fair Value Of Embla Medical hf. (CPH:EMBLA)

Jul 17

Market Participants Recognise Embla Medical hf.'s (CPH:EMBLA) Earnings

May 14

Embla Medical hf. Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now

Apr 26

A Look At The Fair Value Of Embla Medical hf. (CPH:OSSR)

Apr 10

Is Össur hf (CPH:OSSR) Using Too Much Debt?

Mar 23

Why Investors Shouldn't Be Surprised By Össur hf.'s (CPH:OSSR) P/E

Jan 21

Calculating The Intrinsic Value Of Össur hf. (CPH:OSSR)

Jan 03

Össur hf (CPH:OSSR) Seems To Use Debt Quite Sensibly

Nov 28

Returns On Capital Signal Tricky Times Ahead For Össur hf (CPH:OSSR)

Nov 08

A Look At The Fair Value Of Össur hf. (CPH:OSSR)

Sep 23

We Think Össur hf (CPH:OSSR) Is Taking Some Risk With Its Debt

Aug 21

Össur hf (CPH:OSSR) May Have Issues Allocating Its Capital

Jul 18

Össur hf.'s (CPH:OSSR) Intrinsic Value Is Potentially 19% Below Its Share Price

Jun 14

Össur hf (CPH:OSSR) Seems To Use Debt Quite Sensibly

May 19

Össur hf (CPH:OSSR) Might Be Having Difficulty Using Its Capital Effectively

Mar 14

A Look At The Intrinsic Value Of Össur hf. (CPH:OSSR)

Jan 21

These 4 Measures Indicate That Össur hf (CPH:OSSR) Is Using Debt Reasonably Well

Dec 22

There Are Reasons To Feel Uneasy About Össur hf's (CPH:OSSR) Returns On Capital

Dec 07

Are Investors Undervaluing Össur hf. (CPH:OSSR) By 37%?

Sep 21

Returns On Capital Signal Tricky Times Ahead For Össur hf (CPH:OSSR)

Sep 02

Össur hf (CPH:OSSR) Seems To Use Debt Quite Sensibly

Aug 16

Össur hf.'s (CPH:OSSR) Intrinsic Value Is Potentially 42% Above Its Share Price

Jun 16

Össur hf (CPH:OSSR) Will Want To Turn Around Its Return Trends

Jun 01

Does Össur hf (CPH:OSSR) Have A Healthy Balance Sheet?

May 08

Össur hf (CPH:OSSR) Will Be Hoping To Turn Its Returns On Capital Around

Feb 22

Análisis de la situación financiera

Pasivos a corto plazo: Los activos a corto plazo ($419.3M) de EMBLA superan a sus pasivos a corto plazo ($241.1M).

Pasivo a largo plazo: Los activos a corto plazo ($419.3M) de EMBLA no cubren sus pasivos a largo plazo ($545.9M).

Historial y análisis de deuda-patrimonio

Nivel de deuda: El ratio deuda neta-patrimonio (35.4%) de EMBLA se considera satisfactorio.

Reducción de la deuda: El ratio deuda-patrimonio de EMBLA ha pasado de 54.9% a 46.9% en los últimos 5 años.

Cobertura de la deuda: La deuda de EMBLA está bien cubierta por el flujo de caja operativo (33.5%).

Cobertura de intereses: Los pagos de intereses de la deuda de EMBLA están bien cubiertos por el BAIT (5.9x cobertura).

Hoja de balance

Descubre empresas con salud financiera

Análisis de la empresa y estado de los datos financieros

Datos	Última actualización (huso horario UTC)
Análisis de la empresa	2025/05/16 22:18
Precio de las acciones al final del día	2025/05/16 00:00
Beneficios	2025/03/31
Ingresos anuales	2024/12/31

Fuentes de datos

Los datos utilizados en nuestro análisis de empresas proceden de S&P Global Market Intelligence LLC. Los siguientes datos se utilizan en nuestro modelo de análisis para generar este informe. Los datos están normalizados, lo que puede introducir un retraso desde que la fuente está disponible.

Paquete	Datos	Marco temporal	Ejemplo Fuente EE.UU. ^*
Finanzas de la empresa	10 años	Cuenta de resultados Estado de tesorería Balance	Formulario SEC 10-K Formulario SEC 10-Q
Estimaciones del consenso de analistas	+3 años	Previsiones financieras Objetivos de precios de los analistas	Informes de análisis Blue Matrix
Precios de mercado	30 años	Precios de las acciones Dividendos, escisiones y acciones	Datos de mercado ICE Formulario S-1 de la SEC
Propiedad	10 años	Accionistas principales Información privilegiada	Formulario SEC 4 Formulario SEC 13D
Gestión	10 años	Equipo directivo Consejo de Administración	Formulario SEC 10-K Formulario SEC DEF 14A
Principales avances	10 años	Anuncios de empresas	Formulario SEC 8-K

^* Ejemplo para valores de EE.UU., para no EE.UU. se utilizan formularios y fuentes normativas equivalentes.

A menos que se especifique lo contrario, todos los datos financieros se basan en un periodo anual, pero se actualizan trimestralmente. Esto se conoce como datos de los últimos doce meses (TTM) o de los últimos doce meses (LTM). Más información.

Modelo de análisis y copo de nieve

Los detalles del modelo de análisis utilizado para generar este informe están disponibles en nuestra página de Github, también tenemos guías sobre cómo utilizar nuestros informes y tutoriales en Youtube.

Conozca al equipo de talla mundial que diseñó y construyó el modelo de análisis Simply Wall St.

Métricas industriales y sectoriales

Simply Wall St calcula cada 6 horas nuestras métricas sectoriales y de sección. Los detalles de nuestro proceso están disponibles en Github.

Fuentes analistas

Embla Medical hf. está cubierta por 10 analistas. 4 de esos analistas presentaron las estimaciones de ingresos o ganancias utilizadas como datos para nuestro informe. Las estimaciones de los analistas se actualizan a lo largo del día.

Analista	Institución
null null	ABG Sundal Collier
null null	ABG Sundal Collier Sponsored
Niels Granholm-Leth	Carnegie Investment Bank AB

Salud financiera de hoja de balance de Embla Medical hf

Salud financiera controles de criterios 5/6

Información clave

Actualizaciones recientes sobre salud financiera

Here's Why Embla Medical hf (CPH:EMBLA) Can Manage Its Debt Responsibly

Embla Medical hf (CPH:EMBLA) Seems To Use Debt Quite Sensibly

Is Össur hf (CPH:OSSR) Using Too Much Debt?

Össur hf (CPH:OSSR) Seems To Use Debt Quite Sensibly

We Think Össur hf (CPH:OSSR) Is Taking Some Risk With Its Debt

Össur hf (CPH:OSSR) Seems To Use Debt Quite Sensibly

Recent updates

Price target decreased by 8.0% to kr.33.13

First quarter 2025 earnings: EPS misses analyst expectations

Embla Medical Hf. Appoints Conal Harte as Executive Vice President of Patient Care

Now 21% undervalued after recent price drop

Consensus EPS estimates fall by 12%

Price target decreased by 10% to kr.34.75

Embla Medical hf.'s (CPH:EMBLA) Share Price Matching Investor Opinion

Price target decreased by 7.0% to kr.36.50

Here's Why Embla Medical hf (CPH:EMBLA) Can Manage Its Debt Responsibly

Embla Medical hf.'s (CPH:EMBLA) CEO Will Probably Find It Hard To See A Huge Raise This Year

Embla Medical Appoints André Rocha Executive Vice President of Research and Development

Investors Met With Slowing Returns on Capital At Embla Medical hf (CPH:EMBLA)

Acquisition Of Fior & Gentz And New Product Launches Will Expand Neuro Orthotics Portfolio Into New Markets

Embla Medical hf. Just Missed EPS By 5.8%: Here's What Analysts Think Will Happen Next

Full year 2024 earnings: EPS misses analyst expectations

Now 21% undervalued after recent price drop

A Look At The Intrinsic Value Of Embla Medical hf. (CPH:EMBLA)

We Ran A Stock Scan For Earnings Growth And Embla Medical hf (CPH:EMBLA) Passed With Ease

Shareholders Should Be Pleased With Embla Medical hf.'s (CPH:EMBLA) Price

Embla Medical hf. to Report Q3, 2025 Results on Oct 21, 2025

Embla Medical hf (CPH:EMBLA) Seems To Use Debt Quite Sensibly

Results: Embla Medical hf. Beat Earnings Expectations And Analysts Now Have New Forecasts

Third quarter 2024 earnings released: EPS: US$0.051 (vs US$0.033 in 3Q 2023)

Estimating The Intrinsic Value Of Embla Medical hf. (CPH:EMBLA)

Now 21% undervalued

Do Embla Medical hf's (CPH:EMBLA) Earnings Warrant Your Attention?

Embla Medical hf.'s (CPH:EMBLA) Share Price Matching Investor Opinion

Earnings Beat: Embla Medical hf. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models

Second quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

Embla Medical hf. Revises Earnings Guidance for the Full Year of 2024

Calculating The Fair Value Of Embla Medical hf. (CPH:EMBLA)

Market Participants Recognise Embla Medical hf.'s (CPH:EMBLA) Earnings

Embla Medical hf. Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now

First quarter 2024 earnings released: EPS: US$0.019 (vs US$0.024 in 1Q 2023)

New minor risk - Financial position

A Look At The Fair Value Of Embla Medical hf. (CPH:OSSR)

Is Össur hf (CPH:OSSR) Using Too Much Debt?

Össur hf. Appoints Caroline Vagner Rosenstand to the Audit Committee

Investor sentiment improves as stock rises 15%

Full year 2023 earnings: EPS misses analyst expectations

Össur hf. Provides Earnings Guidance for the Year 2024

Why Investors Shouldn't Be Surprised By Össur hf.'s (CPH:OSSR) P/E

Calculating The Intrinsic Value Of Össur hf. (CPH:OSSR)

Össur hf. to Report Q1, 2024 Results on Apr 23, 2024

Össur hf., Annual General Meeting, Mar 12, 2025

Össur hf (CPH:OSSR) Seems To Use Debt Quite Sensibly

Returns On Capital Signal Tricky Times Ahead For Össur hf (CPH:OSSR)

Third quarter 2023 earnings released: EPS: US$0.033 (vs US$0.016 in 3Q 2022)

Össur hf. Reaffirms Financial Guidance for the Year 2023

A Look At The Fair Value Of Össur hf. (CPH:OSSR)

We Think Össur hf (CPH:OSSR) Is Taking Some Risk With Its Debt

Second quarter 2023 earnings: EPS misses analyst expectations

Össur hf (CPH:OSSR) May Have Issues Allocating Its Capital

Össur hf. Announces Executive Changes

Össur hf.'s (CPH:OSSR) Intrinsic Value Is Potentially 19% Below Its Share Price

Össur hf (CPH:OSSR) Seems To Use Debt Quite Sensibly

First quarter 2023 earnings released: EPS: US$0.024 (vs US$0.022 in 1Q 2022)

Össur hf (CPH:OSSR) Might Be Having Difficulty Using Its Capital Effectively

Consensus EPS estimates fall by 12%

Full year 2022 earnings: Revenues in line with analyst expectations

Össur hf. Provides Earnings Guidance for the Year 2023

A Look At The Intrinsic Value Of Össur hf. (CPH:OSSR)

Össur hf. to Report Q1, 2023 Results on Apr 25, 2023

These 4 Measures Indicate That Össur hf (CPH:OSSR) Is Using Debt Reasonably Well

There Are Reasons To Feel Uneasy About Össur hf's (CPH:OSSR) Returns On Capital

Less than half of directors are independent

Consensus EPS estimates fall by 23%

Third quarter 2022 earnings released: EPS: US$0.016 (vs US$0.041 in 3Q 2021)

Investor sentiment improved over the past week